siRNA: A Comprehensive Review of Marketed Products till August 2022

Rupali Ghosh

Department of Pharmacy, East West University Bangladesh, Dhaka, Bangladesh.

Md. Iqbal Hossain Nayan

Department of Pharmacy, Northern University Bangladesh, Dhaka, Bangladesh.

Tirtha Nandi *

Temple University, Philadelphia, PA 19140, USA.

*Author to whom correspondence should be addressed.


Small interference RNA (siRNA) is a double-stranded RNA of 21~25 nucleotides. siRNA functions using a natural phenomenon known as RNA interference (RNAi), a gene silencing mechanism. Hypothetically, siRNA can target and regulate the expression of any disease-related gene in a sequence-specific manner. In 1993, this mechanism was noticed in a nematode Caenorhabditis elegans, later discovered in humans. After two decades, in 2018, the first siRNA therapeutics (Patisiran) were developed successfully and got approval from USFDA. Followed by three more siRNA drugs (Givosiran, Lumasiran, and Inclisiran) approved in consecutive years to treat rare, inherited genetic disorders. Recently approved one is Vutisiran with a similar indication of patisiran. Limitation of conventional therapies, this new & standard pharmacotherapy opens a new era of changing the treatment options of human diseases. Six siRNA candidates are in phase III clinical trials and are hoped to enter the pharmaceutical market soon. Challenges faced during the development of these novel therapies were off-target effects, target-specific delivery, cellular uptake, recognition by the innate immune system, limited efficacy, and others. However, chemical modification of the siRNA nucleotides in sugar, base, and phosphate moiety makes it successful in overcoming obstacles. In addition, a non-viral delivery carrier also helped in many aspects during formulation. This study is a narrative review and will summarize pharmacokinetic, pharmacodynamic, design approaches, and other attributes faced during the development of marketed siRNA products.

Keywords: siRNA, RNAi, patisiran, givosiran, lumasiran, inclisiran, LNP, GalNac

How to Cite

Ghosh , Rupali, Md. Iqbal Hossain Nayan, and Tirtha Nandi. 2023. “SiRNA: A Comprehensive Review of Marketed Products till August 2022”. Journal of Advances in Medical and Pharmaceutical Sciences 25 (1):31-43.


Download data is not yet available.


Brosius J, Raabe CAJRb. What is an RNA? A top layer for RNA classification. RNA Biology. 2016;13(2):140-4.

Li J, Liu CFig. Coding or noncoding, the converging concepts of RNAs. Frontiers in Genetics. 2019;10:496.

Hubé F, Francastel C. Coding and non-coding RNAs, the frontier has never been so blurred. Frontiers in genetics. 2018;9:140.

Brosius J, Raabe CARb. What is an RNA? A top layer for RNA classification. RNA biology. 2016;13(2):140-4.

Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews Drug discovery. 2013;12(11): 847-65.

Neumeier J, Meister GJFiPS. siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects. Frontiers in Plant Science. 2021;11: 526455.

Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JSJTJoPAJotPSoGB, Ireland. Non‐coding RNAs: regulators of disease. The Journal of Pathology: A Journal of the Pathological Society of Great Britain. 2010;220(2):126-39.

Zhang P, Wu W, Chen Q, Chen M. Non-coding RNAs and their integrated networks. Journal of integrative bioinformatics. 2019;16(3).

Phillips T. Small non-coding RNA and gene expression: Nature Education. 2008;[Cited 2022 23/7]. 1(1):115:


Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, et al. The microRNAs of Caenorhabditis elegans. Genes Development. 2003;17(8): 991-1008.

Aalto AP, Pasquinelli AEJCoicb. Small non-coding RNAs mount a silent revolution in gene expression. Current Opinion in Cell Biology. 2012;24(3):333-40.

Cai A, Hu Y, Zhou Z, Qi Q, Wu Y, Dong P, et al. PIWI-Interacting RNAs (piRNAs): Promising Applications as Emerging Biomarkers for Digestive System Cancer. Frontiers in Molecular Biosciences. 2022;9.

Thomson T, Lin HJAroc. The biogenesis and function PIWI proteins and piRNAs: progress and prospect. Annual review of cell Developmental Biology. 2009;25:355.

Höck J, Meister G. The Argonaute protein family. Genome biology. 2008;9(2):1-8.

Neumeier J, Meister G. siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects. Frontiers in Plant Science. 2021;11:526455.

Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clinical Pharmacology & Therapeutics. 2020; 108(1):63-72.

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal transduction and targeted therapy. 2020;5(1):101.

Kim DH, Rossi JJJB. RNAi mechanisms and applications. Biotechniques. 2008; 44(5):613-6.

Juliano C, Wang J, Lin H. Uniting germline and stem cells: the function of Piwi proteins and the piRNA pathway in diverse organisms. Annual review of genetics. 2011;45.

Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature chemical biology. 2006;2(12):711-9.

Koutsilieri E, Rethwilm A, Scheller C. The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders. Neuropsychiatric Disorders An Integrative Approach. 2007:43-9.

Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. The Yale Journal of biology medicine. 2012;85(2):187.

Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends in biotechnology. 2010;28(11):570-9.

Chevalier R. si RNA Targeting and Treatment of Gastrointestinal Diseases. Clinical Translational Science. 2019; 12(6):573-85.

Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnology journal. 2011; 6(9):1130-46.

Milhavet O, Gary DS, Mattson MPJPr. RNA interference in biology and medicine. Pharmacological reviews. 2003;55(4): 629-48.

Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, et al. Molecular mechanisms and biological functions of siRNA. International journal of biomedical science: IJBS. 2017;13(2):48.

Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Molecular Therapy-Nucleic Acids. 2015;4:e252.

Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005;123(4):631-40.

Preall JB, Sontheimer EJ. RNAi: RISC gets loaded. Cell. 2005;123(4):543-5.

Leuschner PJ, Ameres SL, Kueng S, Martinez J. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO reports. 2006;7(3):314-20.

Chiu Y-L, Rana TM. siRNA function in RNAi: a chemical modification analysis. Rna. 2003;9(9):1034-48.

Noland CL, Ma E, Doudna JA. siRNA repositioning for guide strand selection by human Dicer complexes. Molecular cell. 2011;43(1):110-21.

Müller M, Fazi F, Ciaudo C. Argonaute proteins: from structure to function in development and pathological cell fate determination. Frontiers in Cell and Developmental Biology. 2020;7:360.

Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642-55.

Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Advanced drug delivery reviews. 2019;144:133-47.

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal transduction and targeted therapy. 2020;5(1):1-25.

Setten RL, Rossi JJ, Han S-p. The current state and future directions of RNAi-based therapeutics. Nature Reviews Drug Discovery. 2019;18(6):421-46.

Subhan MA, Torchilin V. siRNA based drug design, quality, delivery and clinical translation. Nanomedicine: Nanotechnology, Biology and Medicine. 2020;29:102239.

Salzano G, F Costa D, P Torchilin V. siRNA delivery by stimuli-sensitive nanocarriers. Current pharmaceutical design. 2015;21(31):4566-73.

Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Therapeutics and Clinical Risk Management. 2020;16:109.

Wood H. FDA approves patisiran to treat hereditary transthyretin amyloidosis. Nature Reviews Neurology. 2018; 14(10):570.

Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative disease management. 2019;9(1):5-23.

Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurology and therapy. 2020;9(2):301-15.

Hoy SM. Patisiran: first global approval. Drugs. 2018;78(15):1625-31.

Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ. Patisiran pharmacokinetics, pharmacodynamics, and exposure‐response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin‐mediated (hATTR) amyloidosis. The Journal of Clinical Pharmacology. 2020;60(1):37-49.

Kachur E. Novel Therapies for Transthyretin Amyloidosis. US Pharm. 2019;44(8):8-10.

Titze-de-Almeida SS, Brandão PRdP, Faber I, Titze-de-Almeida R. Leading RNA interference therapeutics part 1: silencing hereditary transthyretin amyloidosis, with a focus on patisiran. Molecular diagnosis & therapy. 2020;24(1):49-59.

Zhang X, Goel V, Robbie GJ. Pharmacokinetics of Patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin‐mediated amyloidosis. The Journal of Clinical Pharmacology. 2020; 60(5):573-85.

Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis–a new wave of hope after years of stagnancy? European Journal of Heart Failure. 2020;22(1):39-53.

Harikrishnan P, Yandrapalli S, Aronow WS, Lanier GM, Jain D. Novel drug therapies for cardiac amyloidosis. Expert Opinion on Investigational Drugs. 2019;28(6):497-9.

Rizk M, Tüzmen Ş. Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran. Pharmacogenomics and personalized medicine. 2017;10:267.

Yang J. Patisiran for the treatment of hereditary transthyretin- mediated amyloidosis. Expert review of clinical pharmacology. 2019;12(2):95-9.

Shahryari A, Nazari Z, Jazi MS, Hashemi-Shahraki F, Wißmiller K, Xu W, et al. Pharmacological Aspects of Clinically Approved Gene Therapy Drugs and Products. 2022.

Honor A, Rudnick S, Bonkovsky H. Givosiran to treat acute porphyria. Drugs of Today (Barcelona, Spain: 1998). 2021; 57(1):47-59.

Gonzalez-Aseguinolaza G. Givosiran—running RNA interference to fight porphyria attacks. Mass Medical Soc. 2020;42:366-7.

Scott LJ. Givosiran: first approval. Drugs. 2020;80(3):335-9.

Syed YY. Givosiran: a review in acute hepatic porphyria. Drugs. 2021;81(7): 841-8.

Majeed CN, Ma CD, Xiao T, Rudnick S, Bonkovsky HL. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. 2022;16:1827.

Alexandre J. DJV, Matthew Catley, David Blakey, Nagy Habib. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Molecular Therapy. 2020;28(8): 1759-71.

Li J, Liu J, Zhang X, Clausen V, Tran C, Arciprete M, et al. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic. Drug Metabolism and Disposition. 2021;49(7):572-80.

Frishberg Y, Deschênes G, Groothoff JW, Hulton S-A, Magen D, Harambat J, et al. Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clinical Journal of the American Society of Nephrology. 2021;16(7):1025-36.

Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. New England journal of medicine. 2021;384(13):1216-26.

Scott LJ, Keam SJ. Lumasiran: first approval. Drugs. 2021;81(2):277-82.

D’Ambrosio V, Ferraro PM. Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside. International Journal of Nephrology and Renovascular Disease. 2022;15:197.

Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong X-b. The growth of siRNA-based therapeutics: Updated clinical studies. Biochemical Pharmacology. 2021;189:114432.

Bacchetta J, Lieske JC. Primary hyperoxaluria type 1: novel therapies at a glance. Clinical Kidney Journal. 2022; 15(Supplement_1):i17-i22.

Hulton S-A. Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1. Expert Opinion on Orphan Drugs. 2021;9(7-10):189-98.

German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34(1):1-9.

Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389-95.

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40.

Bege M, Borbás A. The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides. Pharmaceuticals. 2022;15(8):909.

Merćep I, Friščić N, Strikić D, Reiner Ž. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9—a narrative review. Cardiovascular Therapeutics. 2022;2022.

Warden BA, Duell PB. Inclisiran: a novel agent for lowering Apolipoprotein B–containing lipoproteins. Journal of Cardiovascular Pharmacology. 2021;78(2):e157-e74.

Paul A, Muralidharan A, Biswas A, Kamath BV, Joseph A, Alex AT. siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy. OpenNano. 2022: 100063.

Sirbu CA, Ivan R, Authier FJ, Ionita-Radu F, Jianu DC, Vasiliu O, et al. Orphan Drugs in Neurology—A Narrative Review. Journal of Personalized Medicine. 2023;13(3): 420.

Tschöpe C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. Journal of Clinical Medicine. 2022;11(8):2148.

Friedrich M, Aigner, A. Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs; 2022.


Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic. Journal of Clinical Lipidology. 2022.

Gertz MA, Mauermann ML, Grogan M, Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain and Behavior. 2019; 9(9):e01371.

Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyrias: review and recent progress. Hepatology Communications. 2019;3(2):193-206.